

## H1000.H15C Lot No. HC3-3A

Cryopreserved Human Hepatocytes

**Donor Information** 

 Demographics
 Serology

 Gender:
 Male
 CMV: (+)

 Age:
 35 Years
 HIV: (-)

 Race:
 Hispanic
 HBV: (-)

 Cause of Death:
 Head Trauma
 HCV: (-)

Assured Minimum Yield: 6.0 x 10<sup>6</sup> per vial

Viability: 76.5%

(Yield and viability are based on experiments performed at XenoTech using XenoTech's thawing protocol and Hepatocyte Isolation Kit.)

Enzyme	Marker substrate reaction (pmol/cells per inc/min)	
CYP1A2	Phenacetin O-dealkylation	53.0 ± 8.0
CYP2A6	Coumarin 7-hydroxylation	13.9 ± 1.1
CYP2B6	Bupropion hydroxylation	17.4 ± 1.9
CYP2C8	Amodiaquine <i>N</i> -dealkylation	114 ± 7
CYP2C9	Diclofenac 4'-hydroxylation	$547 \pm 58$
CYP2C19	S-Mephenytoin 4'-hydroxylation	19.8 ± 2.3
CYP2D6	Dextromethorphan O-demethylation	$81.4 \pm 3.9$
CYP2E1	Chlorzoxazone 6-hydroxylation	$238 \pm 26$
CYP3A4/5	Testosterone 6β-hydroxylation	$83.4 \pm 2.1$
CYP3A4/5	Midazolam 1'-hydroxylation	14.9 ± 2.5
CYP4A11	Lauric acid 12-hydroxylation	$48.9 \pm 0.7$

**CAUTION:** These hepatocyte samples are from donors who tested negative for HIV and hepatitis. However, we recommend that these samples be considered as potential biohazards and that universal precautions be used when working with human derived products.

## Store vials in liquid nitrogen, vapor phase.



Data sheet prepared 1/16/09